CD8A and neoplasm: Hiltonol® induces killer-cell targeting (chemotaxis) and tumor vascular endothelial infiltration and supports the host’s ability to overcome immune suppression “checkpoints” in the tumor microenvironment (TME) via a cluster of differentiation 8 (CD8) boost with anti-programmed cell death-1 (aPD-1) checkpoint blockers.